All the news Showing 10 of 81 articles from: Protease inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections Keith Alcorn / 11 April 2014 A 12-week course of three direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1 infection, Professor Stefan Zeuzem of the JW Goethe University Hospital, Frankfurt, ... WHO recommends global use of newest hepatitis C drugs, urges price reductions Keith Alcorn / 09 April 2014 The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for genotypes 1, 2, 3 and 4 or ... Interferon-free BMS combo cures 90% of genotype 1 hepatitis C Liz Highleyman / 27 March 2014 An all-oral regimen of daclatasvir, asunaprevir and BMS-791325 – without interferon or ribavirin – led to sustained response in approximately 90% of people with hepatitis C virus (HCV) who had not previously ... Daclatasvir plus simeprevir are effective against hepatitis C genotype 1b Liz Highleyman / 25 March 2014 An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85 to 95% of people with hepatitis C genotype 1b, but this combination did not work ... Merck combination suppresses HCV in mono-infected and co-infected patients Liz Highleyman / 25 March 2014 An all-oral combination of the hepatitis C virus (HCV) protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people with HIV and HCV co-infection and ... Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection Keith Alcorn / 21 March 2014 The hepatitis C protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured hepatitis C in nearly three-quarters of people with genotype 1 hepatitis C virus (HCV) and HIV co-infection in ... Simeprevir cures almost 80% of first-time co-infected hepatitis C patients Keith Alcorn / 14 March 2014 The next-generation hepatitis C protease inhibitor simeprevir cured almost 80% of previously untreated people with hepatitis C and HIV co-infection when used in combination with pegylated interferon and ribavirin, Prof. Doug Dieterich of ... AbbVie '3D' combination cures 99% of genotype 1b hepatitis C Keith Alcorn / 14 March 2014 A 12-week triple combination of direct-acting antivirals developed by AbbVie cured at least 99% of previously untreated people with genotype 1b hepatitis C infection, Prof. Rajendar Reddy of the University of Pennsylvania Hospital ... US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... Faldaprevir safe and effective in HCV treatment-experienced patients Michael Carter / 13 December 2013 Triple therapy including the investigational hepatitis C virus (HCV) protease inhibitor faldaprevir is a safe and effective treatment for people who did not respond to a previous course of HCV treatment, results of ... ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive